← ANALYST RATINGS · TIPRANKS
BioNTech SE (BNTX): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy3 Hold0 Sell
Ratings of 12 analysts in the last 3 months · top analysts only12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $129, the highest $140, the lowest $105. The average is +47.5% from the last price of $87.71.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $95.00 → $94.00−1.1% | Hold | +7.2% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $92.00 → $91.00−1.1% | Hold | +3.8% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $91.00 → $90.00−1.1% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $90.00 → $89.00−1.1% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $94.00 → $93.00−1.1% | Hold | +6.0% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $91.00 → $90.00−1.1% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $127 | Buy | +44.8% | Reiterated | 13.10.26on TipRanks Oct 14 09:35 | −7.1%next day +0.7% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $130 | Buy | +48.2% | Reiterated | 13.10.26on TipRanks 14:07 | −7.1%next day +0.7% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $125 | Buy | +42.5% | Reiterated | 13.10.26on TipRanks 10:50 | −7.1%next day +0.7% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $105 | Hold | +19.7% | Reiterated | 12.10.26on TipRanks 09:06 | −1.1%next day −7.1% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $114 | Buy | +30.0% | Assigned | 12.10.26on TipRanks 08:15 | −1.1%next day −7.1% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $136 → $132−2.9% | Buy | +50.5% | Reiterated | 12.10.26on TipRanks 06:50 | −1.1%next day −7.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $122 → $114−6.6% | Buy | +30.0% | Reiterated | 09.10.26on TipRanks 06:11 | +4.7%next day −1.1% · 5 days −7.6% | ↗ |
| John Eade★★★★★★★★★★#268 · hits 66% · avg +15.0% | Argus Research | — | Hold | — | Initiated | 08.10.26on TipRanks 08:45 | −2.9%next day +4.7% · 5 days −1.7% | ↗ |
| Luisa Hector★★★★★★★★★★#3558 · hits 58% · avg +4.9% | Berenberg Bank | $140 | Buy | +59.6% | Reiterated | 07.10.26on TipRanks 04:05 | −0.3%next day −2.9% · 5 days −5.9% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $96.00 | Hold | +9.5% | Reiterated | 25.09.26on TipRanks 13:21 | −1.3%next day +1.3% · 5 days −1.4% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $140 | Buy | +59.6% | Reiterated | 24.09.26on TipRanks Sep 25 03:55 | +0.9%next day −1.3% · 5 days −2.0% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $135 | Buy | +53.9% | Reiterated | 16.09.26on TipRanks 04:50 | −0.4%next day +1.8% · 5 days +0.7% | ↗ |
| Harry Gillis★★★★★★★★★★#1398 · hits 69% · avg +21.0% | Berenberg Bank | $132 → $140+6.1% | Buy | +59.6% | Reiterated | 15.09.26on TipRanks Sep 16 01:30 | −1.7%next day −0.4% · 5 days +2.0% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $138 | Buy | +57.3% | Reiterated | 15.09.26on TipRanks 12:05 | −1.7%next day −0.4% · 5 days +2.0% | ↗ |
| Emmanuel Papadakis★★★★★★★★★★#2736 · hits 53% · avg +3.9% | Deutsche Bank | $140 | Buy | +59.6% | Reiterated | 26.08.26on TipRanks 06:11 | −1.3%next day −1.7% · 5 days −7.7% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Hold | — | Reiterated | 19.08.26on TipRanks Aug 20 08:55 | +21.8%next day −1.1% · 5 days −0.1% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $94.00 | Hold | +7.2% | Reiterated | 05.05.26on TipRanks 16:35 | −1.6%next day −2.0% · 5 days −4.3% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $130 | Buy | +48.2% | Reiterated | 27.04.26on TipRanks 06:25 | −3.4%next day +0.5% · 5 days −3.1% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $155 | Buy | +76.7% | Reiterated | 13.03.26on TipRanks Mar 11 09:06 | +8.4%next day +0.7% · 5 days +1.3% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $181 → $167−7.7% | Buy | +90.4% | Reiterated | 11.03.26on TipRanks Mar 10 15:10 | −17.7%next day +8.4% · 5 days +14.0% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $113 | Hold | +28.8% | Downgrade | 02.02.26on TipRanks 06:10 | −4.8%next day +0.3% · 5 days +1.6% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $115 → $117+1.7% | Hold | +33.4% | Reiterated | 06.11.25on TipRanks 09:40 | +1.0%next day −0.3% · 5 days +0.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering BioNTech SE
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $127 at a price of $96.90 (+30.9%); now: $126 at $87.71 (+43.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 4 | 3 | 4 | 3 | 2 |
| Buy | 17 | 9 | 9 | 17 | 27 | 31 |
| Hold | 4 | 3 | 2 | 2 | 4 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.84 (from $-0.02 to $1.53). Last quarter: $-3.64.
Sales
Next quarter’s sales estimate — $1.2B (from $954M to $1.4B). Last quarter: $123M.
Best top-analyst consensus in the sector · Healthcare
About BioNTech SE
- CEO: Ugur Sahin
- Employees: 7,807
- An der Goldgrube 12, Mainz, RP, 55131, DE
- www.biontech.com/de/de/home.html
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genen
Data from the stock’s TipRanks forecast page, read 15 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗